Journal of Hematology & Oncology

Papers
(The TQCC of Journal of Hematology & Oncology is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-12-01 to 2024-12-01.)
ArticleCitations
Targeting the Wnt/β-catenin signaling pathway in cancer823
Nanomaterials for cancer therapy: current progress and perspectives671
NK cell-based cancer immunotherapy: from basic biology to clinical development397
Regulation of PD-L1 expression in the tumor microenvironment365
Challenges and advances in clinical applications of mesenchymal stromal cells348
Next generation of immune checkpoint inhibitors and beyond347
Cancer vaccines as promising immuno-therapeutics: platforms and current progress336
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis323
RNA sequencing: new technologies and applications in cancer research316
Liquid biopsy: current technology and clinical applications315
Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research308
Combination strategies to maximize the benefits of cancer immunotherapy307
Recent advances in therapeutic strategies for triple-negative breast cancer283
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling277
Applications of single-cell sequencing in cancer research: progress and perspectives274
Neutrophils in cancer carcinogenesis and metastasis268
Targeting mutant p53 for cancer therapy: direct and indirect strategies266
Novel therapies emerging in oncology to target the TGF-β pathway255
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response250
Targeting hypoxic tumor microenvironment in pancreatic cancer238
Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells235
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets219
Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019217
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy215
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation207
Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer200
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)198
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy196
Gastric cancer treatment: recent progress and future perspectives196
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies195
Targeting CD47 for cancer immunotherapy190
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape189
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy180
Targeting MCL-1 in cancer: current status and perspectives177
MEK inhibitors for the treatment of non-small cell lung cancer173
Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019167
Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies167
Role of lysosomes in physiological activities, diseases, and therapy164
The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update159
Mesenchymal stem/stromal cells in cancer therapy158
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends156
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin154
Exploring immunotherapy in colorectal cancer151
Antibody–drug conjugates in solid tumors: a look into novel targets146
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single insti144
The management of metastatic GIST: current standard and investigational therapeutics144
N6-methyladenosine methyltransferases: functions, regulation, and clinical potential143
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies139
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1139
Emerging agents and regimens for AML138
Targeting Akt in cancer for precision therapy132
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts129
The potential role of N7-methylguanosine (m7G) in cancer126
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy125
Emerging strategies to target RAS signaling in human cancer therapy121
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma118
HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk116
The long and short non-coding RNAs modulating EZH2 signaling in cancer116
Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients112
The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia112
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma112
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance111
Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications109
Contradictory roles of lipid metabolism in immune response within the tumor microenvironment106
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents103
A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties102
YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma101
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021100
Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer99
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials98
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies97
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential96
New agents and regimens for diffuse large B cell lymphoma95
Advances in the diagnosis and treatment of sickle cell disease93
Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma92
Tumor organoids: applications in cancer modeling and potentials in precision medicine91
LCAT3, a novel m6A-regulated long non-coding RNA, plays an oncogenic role in lung cancer via binding with FUBP1 to activate c-MYC91
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors89
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks88
FGFR-TKI resistance in cancer: current status and perspectives88
HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA88
Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer87
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management87
Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers86
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors85
Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: from mechanism to therapy85
STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib84
Prostate cancer and PARP inhibitors: progress and challenges82
Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity81
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma81
CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR81
T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors81
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation81
Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses79
Payload diversification: a key step in the development of antibody–drug conjugates78
Targeting macrophages in hematological malignancies: recent advances and future directions78
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy78
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)77
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma76
Born to survive: how cancer cells resist CAR T cell therapy75
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy74
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma72
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies72
Emerging strategies to overcome resistance to third-generation EGFR inhibitors71
Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy71
Recent advances in targeted therapies in acute myeloid leukemia71
Metabolism, metabolites, and macrophages in cancer71
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies71
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy71
TGF-β signaling in the tumor metabolic microenvironment and targeted therapies70
Natural killer cell-based immunotherapy for acute myeloid leukemia69
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia69
Cancer cachexia: molecular mechanisms and treatment strategies69
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy69
STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer69
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy68
N6-methyladenosine reader IMP2 stabilizes the ZFAS1/OLA1 axis and activates the Warburg effect: implication in colorectal cancer67
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN167
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies67
Circadian rhythms and cancers: the intrinsic links and therapeutic potentials66
SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism66
Third-line therapy for chronic myeloid leukemia: current status and future directions66
Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study64
The emerging role of KDM5A in human cancer63
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies63
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics63
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies62
Prognostic and predictive biomarker developments in multiple myeloma62
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target62
Thrombocytopenia and thrombosis in hospitalized patients with COVID-1962
Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer62
Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities62
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors62
Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party o61
Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy61
Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes60
Deep learning for differential diagnosis of malignant hepatic tumors based on multi-phase contrast-enhanced CT and clinical data60
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy60
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma60
CAR-T cells and BiTEs in solid tumors: challenges and perspectives60
Molecular pathogenesis of the myeloproliferative neoplasms58
Functions, mechanisms, and therapeutic implications of METTL14 in human cancer57
Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation56
Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism55
CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer54
Exosomal circRNA: emerging insights into cancer progression and clinical application potential53
How we treat NK/T-cell lymphomas53
Advances of medical nanorobots for future cancer treatments53
Therapeutic strategies in RET gene rearranged non-small cell lung cancer53
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials52
Recent advances in targeted strategies for triple-negative breast cancer52
Protein degradation technology: a strategic paradigm shift in drug discovery52
Solamargine induces hepatocellular carcinoma cell apoptosis and autophagy via inhibiting LIF/miR-192-5p/CYR61/Akt signaling pathways and eliciting immunostimulatory tumor microenvironment51
Drugging KRAS: current perspectives and state-of-art review51
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer49
Momelotinib: an emerging treatment for myelofibrosis patients with anemia49
Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application49
RETRACTED ARTICLE: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA49
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma49
Interplay between endoplasmic reticulum stress and non-coding RNAs in cancer48
Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers48
Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients48
Integrins regulate stemness in solid tumor: an emerging therapeutic target48
Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway48
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial48
0.074877023696899